Mark W Prager, DO in Elkton, VA - General Practice

Mark W Prager, DO is a General Practice physician based in Elkton, Virginia. Mark W Prager is licensed to practice in Virginia (license number 0102037012) and his current practice location is 115 E Rockingham St, Elkton, Virginia. He can be reached at his office (for appointments etc.) via phone at (540) 298-1300.

NPI number for Mark W Prager is 1841341187 and his current mailing address is 9834 Business Way, Manassas, Virginia. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1841341187.

Contact Information

	Mark W Prager, DO
	115 E Rockingham St, Elkton, VA 22827-1522
	(540) 298-1300
	(540) 298-9090

Physician's Profile

Full Name	Mark W Prager
Gender	Male
Speciality	General Practice
Location	115 E Rockingham St, Elkton, Virginia
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1841341187
Provider Enumeration Date: 01/15/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mark W Prager such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1841341187	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	0102037012 (Virginia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mark W Prager is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mark W Prager, DO 9834 Business Way, Manassas, VA 20110-4151 Ph: (703) 361-7708	Mark W Prager, DO 115 E Rockingham St, Elkton, VA 22827-1522 Ph: (540) 298-1300

News Archive

NeoPharm first-quarter net loss decreases to $1.4 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.

Specific brain circuit linked to food impulsivity discovered

You're on a diet, but the aroma of popcorn in the movie theater lobby triggers a seemingly irresistible craving.

Scientists develop new therapies to prevent chemoresistance of established tumours

Cancer cells often develop defence mechanisms which enable them to survive chemotherapy. A group of researchers from the Institutes of Pharmacology and Pathology in Bern present new solutions for preventing the development of such resistances.

Acute stress modifies DNA methylation and activity of certain genes

Acute stress alters the methylation of the DNA and thus the activity of certain genes. This is reported by researchers at the Ruhr-Universität Bochum together with colleagues from Basel, Trier and London for the first time in the journal Translational Psychiatry. "The results provide evidence how stress could be related to a higher risk of mental or physical illness", says Prof. Dr. Gunther Meinlschmidt from the Clinic of Psychosomatic Medicine and Psychotherapy at the LWL University Hospital of the RUB.

New understanding of anti-malarial drug resistance

Researchers at Georgetown University Medical Center say they are moving closer to understanding why the most lethal form of human malaria has become resistant to drug treatment in the past three decades.

Mark W Prager, DO - General Practice in Elkton, VA